Regulatory
Published · Updated · 1 min read
DEC: materials on vonoprazan risks and adverse reaction monitoring
What it means for practice
When prescribing vonoprazan, consider the listed potential risks, monitor for adverse reactions and report suspected reactions. Specific monitoring measures should be checked against the original materials.
Summary
The website of the State Expert Centre of the Ministry of Health of Ukraine (DEC) hosts safety communication materials for ХЕЛІПРОЗАН (vonoprazan) intended for healthcare professionals. According to the available abstract, their purpose is to inform healthcare professionals about safe prescribing and monitoring during treatment.
Potential risks
The abstract lists increased gastrin levels, liver problems, fracture risk, gastrointestinal infections and respiratory diseases. These conditions are presented as potential risks; the abstract does not specify their frequency, severity or the characteristics of affected patients.
Implications for practice
The materials emphasize regular medical consultations, monitoring for adverse reactions and reporting suspected adverse reactions to support ongoing benefit–risk assessment. The available description does not provide specific investigation protocols, monitoring intervals or criteria for changing treatment. This digest is based solely on the abstract; practical details should be verified in the original document.
Source
-
dec.gov.ua. Комунікаційні матеріали для спеціалістів системи хорони здоров’я щодо безпеки застосування лікарського засобу ХЕЛІПРОЗАН (вонопразан).
Reviewed by: DrugCard editorial team ·
This article does not replace clinical judgement. Disclaimer
